Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

NCT03684811 is registered in ClinicalTrials.gov with Forma Therapeutics, Inc. as lead sponsor.

NCT NCT03684811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03684811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Lead sponsor
Forma Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
November 1, 2018
Completion date
June 13, 2022
Enrollment
93 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

cohort 1a and 1b: glioma (advanced gliomas and glioblastoma multiforme), cohort 2a and 2b: hepatobiliary tumors (hepatocellular carcinoma, bile duct carcinoma, intrahepatic cholangiocarcinoma, other hepatobiliary carcinomas), cohort 3a and 3b: chondrosarcoma, cohort 4a and 4b: intrahepatic cholangiocarcinoma, cohort 5a: other non-central nervous system solid tumors with idh1 mutations